{"id":"platinum-containing-salvage-chemotherapy","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Peripheral neuropathy"},{"rate":null,"effect":"Mucositis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Platinum compounds (such as cisplatin, carboplatin, or oxaliplatin) bind to DNA and form inter- and intra-strand crosslinks, which block DNA synthesis and repair mechanisms. This leads to apoptosis in rapidly dividing cancer cells. In a salvage setting, these agents are used in patients who have relapsed or are refractory to prior chemotherapy regimens.","oneSentence":"Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:51:54.346Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Relapsed or refractory lymphoma (salvage therapy)"},{"name":"Other platinum-sensitive malignancies in salvage setting"}]},"trialDetails":[{"nctId":"NCT03391466","phase":"PHASE3","title":"Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma","status":"COMPLETED","sponsor":"Kite, A Gilead Company","startDate":"2018-01-25","conditions":"Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)","enrollment":359},{"nctId":"NCT05749887","phase":"NA","title":"The Efficacy of Salvage Surgery in Patients With Residual Tumor After Concurrent Chemoradiation for Locally Advanced Cervical Cancer.","status":"RECRUITING","sponsor":"Chongqing University Cancer Hospital","startDate":"2023-08-25","conditions":"Cervical Cancer","enrollment":188},{"nctId":"NCT00551122","phase":"PHASE1, PHASE2","title":"Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors","status":"UNKNOWN","sponsor":"University of Southampton","startDate":"2006-11","conditions":"Brain and Central Nervous System Tumors, Extragonadal Germ Cell Tumor, Ovarian Cancer","enrollment":23}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":25,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Platinum-containing Salvage Chemotherapy","genericName":"Platinum-containing Salvage Chemotherapy","companyName":"Kite, A Gilead Company","companyId":"kite-a-gilead-company","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Platinum-containing chemotherapy agents work by forming DNA adducts that cross-link DNA strands, preventing replication and transcription, thereby inducing cancer cell death. Used for Relapsed or refractory lymphoma (salvage therapy), Other platinum-sensitive malignancies in salvage setting.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}